23andMe's 'Build-a-Baby' Patent Criticised
By BBC,
BBC News [Quotes CGS's Marcy Darnovsky]
| 10. 03. 2013
A US patent for a database that uses DNA testing to tell prospective parents which traits their future offspring may inherit has been criticised by experts.
23andMe says its Family Traits Inheritor Calculator can predict the risk of inheriting specific diseases as well as details such as height, weight, eye colour and even personality.
Couples send the firm a saliva sample to see what their babies might be like.
But critics have called the project "ethically and socially treacherous".
Designer babies
The patent suggests the database could also be used by fertility clinics to find appropriate donors.
But the Mountain View, California-based firm was quick to say this was no longer part of its plan.
"At the time 23andMe filed the patent, there was consideration that the technology could have potential applications for fertility clinics so language specific to the fertility treatment process was included in the patent," it said in a blog post.
"The company never pursued the concepts discussed in the patent beyond our Family Traits Inheritance Calculator, nor do we have any plans to do...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...